ACELYRIN(SLRN.US)

Company Encyclopedia
View More
name
ACELYRIN
SLRN.US
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company’s lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED). Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.
1.901 T
SLRN.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Climb Bio Files Complaint Against Alumis And Acelyrin - SEC Filing

    Dec 31 (Reuters) - Climb Bio Inc:CLIMB BIO INC - FILES COMPLAINT AGAINST ALUMIS AND ACELYRIN - SEC FILINGCLIMB BIO INC - COMPLAINT RELATING TO A DISPUTE CONCERNING AN ASSET PURCHASE AGREEMENT, DATED AS OF JANUARY 11, 2024CLIMB BIO INC - COMPLAINT SEEKS DECLARATORY JUDGMENT THAT CO’S BUDOPRUTUG DRUG CANDIDATE IS NOT “PRODUCT” UNDER APACLIMB BIO INC - DOES NOT OWE A MILESTONE PAYMENT SOUGHT BY ALUMIS IN CONNECTION WITH ITS DEVELOPMENT OF BUDOPRUTUG Source text: Further company coverage:

    Reuters·
    US
    SLRN
    0.00%
    US
    ALMS
    +7.59%
    Reuters·
    US
    SLRN
    0.00%
    US
    ALMS
    +7.59%

    Climb Bio Sues Alumis Over $3 Million Milestone Dispute

    Climb Bio Inc. has filed a lawsuit against Alumis Inc. and Acelyrin Inc. over a $3 million milestone payment dispute related to a January 2024 Asset Purchase Agreement. Climb claims it was invoiced for the payment after dosing its first patient in a Phase 2 trial, despite not receiving any royalty-bearing patents. The company argues its payment obligations are limited to products infringing patents included in the transferred assets, which it asserts it did not receive. Climb is seeking court intervention to clarify its obligations and resolve the dispute.

    Reuters·
    US
    SLRN
    0.00%
    US
    ALMS
    +7.59%
    Reuters·
    US
    SLRN
    0.00%
    US
    ALMS
    +7.59%

    Acelyrin Inc. Delists from Nasdaq Following Merger, Becomes Wholly Owned Subsidiary of Alumis

    Acelyrin Inc. has completed a merger with Alumis, becoming a wholly owned subsidiary. Following this change of control, Acelyrin has notified Nasdaq to suspend trading of its common stock and plans to delist from Nasdaq and deregister under the Securities Exchange Act of 1934. The company will also terminate its reporting obligations and its 2023 Employee Stock Purchase Plan.

    Reuters·
    US
    SLRN
    0.00%
    Reuters·
    US
    SLRN
    0.00%

    ACELYRIN Inc reports results for the quarter ended March 31 - Earnings Summary

    ACELYRIN Inc reported a quarterly adjusted loss of 55 cents per share for the quarter ended March 31, compared to a loss of 36 cents per share in the same quarter last year. The company reported a total loss of $55.26 million with zero revenue. ACELYRIN shares fell by 17.2% this quarter and 34.9% year-to-date. Analysts maintain a "strong buy" rating with a median 12-month price target of $8.00. The earnings estimate for the next quarter was missed by 5 cents.

    Reuters·
    US
    SLRN
    0.00%
    Reuters·
    US
    SLRN
    0.00%

    Alumis Inc. Stockholders Approve Merger with ACELYRIN, Anticipating Successful Close in Q2 2025

    Alumis Inc. stockholders have approved the merger with ACELYRIN, expected to close in Q2 2025. The merger aims to enhance value for both companies' stockholders, with ACELYRIN stockholders receiving 0.4814 shares of Alumis common stock per share. Post-merger, Alumis stockholders will own approximately 52% of the combined entity, while ACELYRIN stockholders will hold around 48%. The merger is anticipated to advance a differentiated clinical pipeline and provide financial flexibility for strategic opportunities in immune-mediated diseases.

    Reuters·
    US
    SLRN
    0.00%
    US
    ALMS
    +7.59%
    Reuters·
    US
    SLRN
    0.00%
    US
    ALMS
    +7.59%
    © 2026 Longbridge｜Disclaimer